Skip to main content

Table 10 Overall relative risks and 95% confidence interval according to cancer site and type of exposure

From: Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis

 

N†

NSAIDs RR (95%CI)

N

Aspirin RR (95%CI)

N

NA-NSAIDs RR (95%CI)

Esophagus

4

0.65 (0.46–0.92)

4

0.51 (0.38–0.69)

  

Stomach

3

0.54 (0.39–0.75)

5

0.73 (0.63–0.84)

2

0.91 (0.66–1.25)

Pancreas

2

1.09 (0.59–2.01)

3

0.69 (0.40–1.20)

  

Breast

9

0.77* (0.66–0.88)

11

0.77 (0.69–0.86)

5

0.86 (0.73–1.00)

Ovary

6

0.74 (0.61–0.90)

6

0.91 (0.79–1.06)

  

Prostate

4

0.64* (0.34–1.21)

7

0.92 (0.81 – 1.05)

2

0.84 (0.68–1.05)

Kidney

  

6

1.23* (0.86–1.75)

  

Bladder

3

0.91 (0.71–1.18)

3

0.91 (0.73–1.13)

  

Lung

3

0.65* (0.34–1.22)

5

0.84* (0.66–1.07)

  
  1. *p < 0.05 (Heterogeneity test); †Number of studies.